摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

[(4R,5R)-5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol | 145554-06-9

中文名称
——
中文别名
——
英文名称
[(4R,5R)-5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol
英文别名
(4R,5R)-(5-((1-tert-butyl-1,1-dimethylsilyloxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol;((4R,5R)-5-(((tert-butyl-dimethyl)silyl-oxy)-methyl)-2,2-dimethyl 1,3-dioxolan-4-yl) methanol;((4R,5R)-5-(((tert-butyl-dimethyl)silyl-oxy)-methyl)-2,2-dimethyl 1,3-dioxolan-4-yl)methanol;((4R,5R)-5-(((tert-butyldimethylsilyl)oxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol;((4R,5R)-5-((tert-butyldimethylsilanyloxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol;((4R,5R)-5-((tert-butyldimethylsilyloxy)methyl)-2,2-dimethyl-1,3-dioxolan-4-yl)methanol;[(4R,5R)-5-[[tert-butyl(dimethyl)silyl]oxymethyl]-2,2-dimethyl-1,3-dioxolan-4-yl]methanol
[(4R,5R)-5-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol化学式
CAS
145554-06-9
化学式
C13H28O4Si
mdl
——
分子量
276.448
InChiKey
AKGOASLTMRVWBH-GHMZBOCLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    323.6±27.0 °C(Predicted)
  • 密度:
    0.953±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.52
  • 重原子数:
    18
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    47.9
  • 氢给体数:
    1
  • 氢受体数:
    4

SDS

SDS:7d0968dbf14deb7e5e6b9b940b5d38bb
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] ARYLOXYACETYLINDOLES AND ANALOGS AS ANTIBIOTIC TOLERANCE INHIBITORS<br/>[FR] ARYLOXYACÉTYLINDOLES ET ANALOGUES EN TANT QU'INHIBITEURS DE TOLÉRANCE AUX ANTIBIOTIQUES
    申请人:SPERO THERAPEUTICS INC
    公开号:WO2016112088A1
    公开(公告)日:2016-07-14
    The disclosure provides compounds and pharmaceutical compositions of aryloxyacetylindoles compounds and analogs useful for treating chronic and acute bacterial infections. Certain of the compounds are compounds of general Formula (I) (I) or a pharmaceutically acceptable salt or prodrug thereof. Certain compounds of this disclosure are MvfR inhibitors. MvfR inhibitors reduce the formation of antibiotic tolerant bacterial strains and are useful for treating Gram-negative bacterial infections and reducing the virulence of Pseudomonas aeruginosa. Methods of treating bacterial infections in a subject, including Pseudomonas aeruginosa infections, are also provided by the disclosure.
    该披露提供了芳基氧乙酰基吲哚化合物及类似物的化合物和药物组合物,用于治疗慢性和急性细菌感染。其中某些化合物是一般式(I)(I)的化合物或其药用可接受的盐或前药。该披露的某些化合物是MvfR抑制剂。MvfR抑制剂减少抗生素耐药细菌菌株的形成,对治疗革兰氏阴性细菌感染和减少铜绿假单胞菌的毒力有用。该披露还提供了治疗受试者细菌感染的方法,包括铜绿假单胞菌感染。
  • Synthesis of the C5–C30 fragment of cyclodidemniserinol trisulfate via I2-mediated deprotection and ring closure tandem reaction
    作者:Jian-Hua Liu、Yi Jin、Ya-Qiu Long
    DOI:10.1016/j.tet.2009.12.024
    日期:2010.2
    The marine natural product cyclodidemniserinol trisulfate displayed moderate HIV-1 integrase inhibitory activity. Its novel structure triggered our interest to synthesize it. In our total synthesis effort, the natural product was dissected into four fragments based on the rational retrosynthetic analysis. All four fragments were successfully prepared with orthogonal protection. And the assembly of
    海洋天然产物环硫酸二环亚氨基三醇显示出中等的HIV-1整合酶抑制活性。它的新颖结构激发了我们对其进行合成的兴趣。在我们的总合成努力中,基于合理的逆向合成分析,将天然产物分为四个片段。用正交保护成功制备了所有四个片段。在NaHCO 3存在下,通过I 2介导的脱保护和分子内缩酮形成串联反应,片段A和片段B的装配提供了C 5 –C 30关键亚基。在MeCN中。我们的工作提供了灵活实用的方法来合成和衍生基于3,5,7-三取代的6,8-二氧杂双环[3.2.1]辛烷的类似物,以寻找新的结构HIV-1整合酶抑制剂。
  • Synthesis of an Acyclic C1-C11 Fragment of Peloruside B
    作者:Qin Zang、Shivali Gulab、Bridget L. Stocker、Sylvia Baars、John O. Hoberg
    DOI:10.1002/ejoc.201100053
    日期:2011.8
    The synthesis of a C1 reduced form of the C1–C11 fragment of peloruside B has been achieved in 15 synthetic steps. The strategy involved the use of D-tartaric acid to set the absolute stereochemistry and a 1,5-anti Mukiayama aldol reaction. Analog synthesis of C8–C11 is also reported, which enables changes at the C10 position of peloruside B to be made. The synthesis of the fragment concludes with
    peloruside B 的 C1-C11 片段的 C1 还原形式的合成已在 15 个合成步骤中实现。该策略涉及使用 D-酒石酸来设置绝对立体化学和 1,5-抗 Mukiayama 羟醛反应。还报告了 C8-C11 的模拟合成,这使得 peloruside B 的 C10 位置发生变化。片段的合成以受保护的醇状态而不是天然酯的 C1 结束。
  • Total Synthesis of Phorboxazole A. 1. Preparation of Four Subunits
    作者:James D. White、Punlop Kuntiyong、Tae Hee Lee
    DOI:10.1021/ol062530r
    日期:2006.12.1
    [Structure: see text] Four subunits of the potent antitumor agent phorboxazole A were constructed; fragments C20-C32 and C9-C19 containing tetrahydropyrans A and B, respectively, were assembled using palladium-catalyzed intramolecular alkoxycarbonylation.
    [结构:见正文]构建了有效的抗肿瘤药佛波唑A的四个亚基。使用钯催化的分子内烷氧基羰基化反应分别组装含有四氢吡喃A和B的C20-C32和C9-C19片段。
  • Highly (<i>E</i>)-Selective Wadsworth−Emmons Reactions Promoted by Methylmagnesium Bromide
    作者:Timothy D. W. Claridge、Stephen G. Davies、James A. Lee、Rebecca L. Nicholson、Paul M. Roberts、Angela J. Russell、Andrew D. Smith、Steven M. Toms
    DOI:10.1021/ol802212e
    日期:2008.12.4
    An experimentally simple protocol for the very highly (E)-selective Wadsworth-Emmons reaction [(E):(Z) selectivities in excess of 180:1 in some cases] of a range of straight-chain and branched aliphatic, substituted aromatic, and base-sensitive aldehydes via reaction with an alkyl diethylphosphonoacetate and MeMgBr is reported.
    对一系列直链和支链脂族,取代芳族化合物进行非常高度(E)选择性的Wadsworth-Emmons反应[(E):( Z)选择性在某些情况下超过180:1的反应)的实验简单方法,报道了通过与烷基二乙基膦酰基乙酸酯和MeMgBr反应生成的对碱敏感的醛。
查看更多